pok-f

The Journal of the Royal Institute of Thailand Vol. 33 No. 2 Apr.-Jun. 2008 80 °≈ÿà ¡‚√§Õâ «π≈ßæÿ ß (Metabolic Syndrome) Assoc Thailand 2007; 90 : 459-67 (ÚÛ) Reichelsen B, Pedersen SB, Moller- Pederson T, Bak JF. Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin and prostaglandin E2. Metabo- lism 1991 ; 40 : 990-6 (ÚÙ) Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis 2003 ; 168 : 351-8. (Úı) Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003 ; 108 : 420-5. (Úˆ) Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo R. Effects of fatty acids on glucose production and utilization in man. J Clin Invest 1983 ; 72 : 1737-47. (Ú˜) Arita Y, Kihara S, Ouchin, et al. Para- doxical decrease of an adipose-specific protein, adeponectin, in obesity. Biochem Biophys Commun 1999 ; 257 : 79-83. (Ú¯) Wyer C, Funahashi T, Tanaka S, et al. Hypoadeponectinemia in obesity and type Ú diabetes : close association with insulin resistance and hyperinsulinemia. J Clin Endoclinol Metab 2001 ; 86 : 1930-5. (Ú˘)Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastro- enterology 2002 ; 123 : 1705-25. (Û)Rowe JW, Younce JB, Minaker KL, Stevens AL, Palotta J, Landsbergl. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981 ; 30 : 219-25. (ÛÒ)Christensen NJ, Gundersen HJG, Hegedus L, et al. Acute effect of insulin on plasma nor adrenaline and cardiovascular system. Metabolism 1980 ; 29 : 1138-45. (ÛÚ) De Fronzo RA, Cooke C, Andres R, Faloona GR, Davis PJ. The effect of in- sulin in renal handling of sodium, potas- sium, calcium and phosphate in man. I Clin Invest 1975 ; 55 : 845-55. (ÛÛ) Grundy SM, Hansen B, Smith SC, et al. Clinical management of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association/National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circula- tion 2004 ; 109 : 551-6 (ÛÙ)Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report, National Institutes of Health. Obes Res. 1998;2(supp 6) : 51S-209S. (Ûı)Lindstrom J, Louheranta A, Mannelin M, for the Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS):lifestyle intervention and 3- year results on diet and physical activity. Diabetes Care 2003 ; 26: 3160-7. (Ûˆ)Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atheroscle- rotic cardiovascular disease: a statement from the American Heart Association council on clinical cardiology and the council on nutrition, physical activity, and metabolism. Circulation 2003 ; 107 : 3106-16. (Û˜)National Cholesterol Education Program Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. JAMA 2001; 285 : 2486-97. (Û¯)He J, Whelton PK, Appel U, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on in- cidence of hypertension. Hypertension 2000; 35 : 544-9. (Û˘)Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detec- tion, evaluation and treatment of high blood pressure. The JNC 7th Report. JAMA 2003 ; 289 : 2560-72. (Ù)Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA. Effects of angiotensin-converting enzyme inhibitors, calcium antagonists and alpha-adrenergic blockers on glucose and lipid metabo- lism in NIDDM patients with hyperten- sion. Diabetes 1995 ; 44 : 665-71. (ÙÒ)The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reserch Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002 ; 288 : 2981-7. (ÙÚ)The Heart Outcomes Prevention Evalua- tion Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in